The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Europe at a Crossroads
The Small Business Perspective: How Owners Are Dealing With Worker Shortages, Inflation and Supply Chain Delays
The Impact of Rising Natural Gas Prices
Why Hedge Funds Are Turning to the Private Markets
Is China Investable?
What’s Behind the Record-Breaking IPO Market?
Outlook for Global Growth: Less Synchronized, More Complicated
How Are Investors Navigating China’s Regulatory Uncertainty?
The Delta Variant: Implications for Vaccines, Booster Shots and Economic Growth
M&A Outlook: How Companies Are Positioning For Growth
Where Are Family Offices Seeking Higher Returns?
The Future of ‘Femtech’
Race to Zero: How Companies Are Deploying Decarbonization Strategies
‘Bidenomics’: Evolution or Revolution?
The Global Chip Shortage: Impact, Outlook and Recovery
The European Recovery: Here to Stay?
From Crisis to Confidence: How Women Entrepreneurs Fared During the Pandemic
Industrials Influx: What’s Fueling Record Activity Levels?
Crypto: A New Asset Class?
What’s Ahead for Inflation?
Create your
podcast in
minutes
It is Free
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money